Bausch & Lomb
This article was originally published in The Tan Sheet
Executive Summary
Sales from continuing businesses for the fiscal fourth quarter ended Dec. 25 totaled $466.6 mil., up 8.9%. Excluding foreign exchange rates, sales increased 11% over the prior-year period. After restructuring charges and the results of discontinued operations, net income for the quarter was $17.2 mil. For the year, sales rose 9.9% to $1.76 bil. Factoring in restructuring charges, a gain on redemption of securities in the third quarter and purchase accounting adjustments and write-offs from 1998, net income reached $444.8 mil. for the year. Bausch & Lomb vision care revenues rose 6% for the quarter, while pharmaceutical sales rose 12%. Domestic sales accounted for 51% of total revenues and jumped 11% in the quarter
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning